A Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Androgen-Independent Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 10 Feb 2017
At a glance
- Drugs ATL 101 Telix Pharmaceuticals (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 03 Oct 2013 Results have been published in Clinical Cancer Research according to an ATLAB Pharma media release.
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.